Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 23Terminated 6Withdrawn 3Unknown 3Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3

Conditions

Carcinoma, Non-Small-Cell Lung 37Breast Neoplasms 26Prostatic Neoplasms 22Stomach Neoplasms 12Squamous Cell Carcinoma of Head and Neck 12Lung Neoplasms 11Neoplasms 10Urinary Bladder Neoplasms 8Head and Neck Neoplasms 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 7Carcinoma, Squamous Cell 6Non-Muscle Invasive Bladder Neoplasms 5Nasopharyngeal Carcinoma 5Carcinoma, Transitional Cell 5Adenocarcinoma 5Oropharyngeal Neoplasms 4Sarcoma 3Prostatic Neoplasms, Castration-Resistant 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Vaccinia 2Recurrence 2Peritoneal Neoplasms 2Metastatic Castration-Resistant Prostate Cancer 2Melanoma 2

Interventions

Doxorubicin 15pembrolizumab 12Cyclophosphamide 9Surgical Procedures, Operative 8Gemcitabine 8Blood Specimen Collection 8Ifosfamide 7Surveys and Questionnaires 6Nivolumab 6Trabectedin 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Drug Therapy 5fludarabine 4Temozolomide 4Specimen Handling 4Radiation Dose Hypofractionation 4Biopsy 4selinexor 3pazopanib 3liposomal doxorubicin 3cabozantinib 3atezolizumab 3anlotinib 3Radiation 3Observation 3Docetaxel 3Dacarbazine 3trastuzumab deruxtecan 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Sarcoma × Docetaxel × Clear all
NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT04577014 2026-04-14

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
98 enrolled
Sarcoma

Sarcoma

NCT04535713 2024-07-05

GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

Sarcoma Oncology Research Center, LLC

Phase 2 Recruiting
260 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡